Biocon reported strong Q2FY26 results with operating revenue up 20% to ₹4,296 Cr. EBITDA increased by 29% to ₹928 crore, and PBT (before exceptional items) surged by 153% to ₹183 Cr. The growth was driven by Biosimilars and Generics businesses. The company inaugurated its first OSD manufacturing facility in the United States. For the quarter, Net Profit stood at ₹85 crore, up 428%.
Financial Highlights for Q2FY26
Biocon Limited announced its consolidated financial results for Q2FY26, ended September 30, 2025, showcasing substantial growth.
- Operating Revenue: Increased by 20% to ₹4,296 Crore.
- EBITDA: Rose by 29% to ₹928 Crore.
- EBITDA Margin: Stood at 21%.
- PBT (before exceptional items): Surged by 153% to ₹183 Crore.
- Net R&D Investment: ₹251 Crore, representing 7% of revenue (excluding Syngene).
Segment Performance
The revenue breakdown by segment is as follows:
- Biosimilars: ₹2,721 Crore, up 25% YoY.
- Generics: ₹774 Crore, up 24% YoY.
- CRDMO (Syngene): ₹911 Crore, up 2% YoY.
Key Developments
The company achieved several significant milestones during the quarter:
- Inaugurated Biocon’s first OSD manufacturing facility in the United States.
- Secured its first global phase III clinical trial from a U.S.-based biotech company for Syngene.
- Biocon Biologics launched four biosimilars across key global markets in FY26.
Sustainability and Recognition
- Biocon’s EcoVadis 2025 score moved up to 74 from 66 last year, placing the company in the 91st percentile.
- The Company received 7 awards from the Quality Circle Forum of India (QCFI) for excellence in Production, Quality and EHS.
Financial Performance Commentary
- Core EBITDA for Q2FY26 was reported at ₹1,218 crore, a 23% increase with core operating margins of 28%.
- Net Profit for the quarter stood at ₹85 crore, marking a substantial increase of 428%.
Source: BSE
